Renoprotective effects and safety of sodium-glucose cotransporter 2 inhibitors in diabetic chronic kidney disease: A systematic review and meta-analysis.
Xiuzhen Shi, Kai Fu, Min Hu et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on patients with diabetic chronic kidney disease (CKD). Involving 29,192 participants from 17 randomized controlled trials, the study found that SGLT2 inhibitors significantly reduced glycated hemoglobin by 0.40%, body weight by 1.36 kg, and systolic blood pressure by 2.98 mm Hg, while showing neutral effects on eGFR and UACR.
Key findings
- SGLT2 inhibitors reduced glycated hemoglobin levels by 0.40% (95% CI: -0.44 to -0.36).
- Body weight decreased by 1.36 kg (95% CI: -1.55 to -1.18) with SGLT2 inhibitors.
- Systolic blood pressure was lowered by 2.98 mm Hg (95% CI: -3.44 to -2.52).
- SGLT2 inhibitors increased the risk of volume depletion-related adverse events (RR = 1.36, 95% CI: 1.16-1.59).
Why it matters
The findings highlight the potential of SGLT2 inhibitors to improve metabolic parameters in diabetic CKD patients, which may contribute to better overall management of the disease. Understanding their safety profile is crucial for clinicians when considering treatment options.